Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Four of six analysts call NVAX stock a buy. From where I sit, they're spot on.

Novavax Far From Finished In the Race for a Vaccine

Abbott Labs

Pfizer

These coronavirus leaders are great picks for different reasons.

3 COVID Stocks That Are Screaming Buys

Two delays should have investors thinking twice about buying the stock.

Novavax Stock: Buy at the High?

Arcturus Therapeutics

BioNTech SE

Johnson & Johnson

Moderna

Vaxart

Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.

COVID Vaccine Stock Ideas for Different Investors

There's something for every kind of investor with this list.

3 Top Coronavirus Stocks to Buy in December

Inovio Pharmaceuticals

Seres Therapeutics

Twist Bioscience Corp

Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.

These 5 Mid-Cap Healthcare Stocks Had the Best Gains in 2020

NVAX stock has faltered lately, as other companies seem to have taken the lead in the Covid-19 vaccine race. But patience will be rewarded.

Take Advantage of Investor Impatience with Novavax

Novavax is in Phase 3 trials with its novel coronavirus vaccine and success there will provide massive momentum for NVAX stock. The post Novavax Stock a Strong Bet to Ride the Vaccination Wave appeared first on InvestorPlace.

Novavax Stock a Strong Bet to Ride the Vaccination Wave

Sanofi

There are plenty of catalysts on the horizon for these investments -- and a healthy dose of risk.

3 Best Biotech Stocks of 2020: Are They Buys Now?

A biotech company and a big pharma player each offer something that sets them apart from rivals.

Forget Moderna! These 2 Stocks May be the Biggest Winners of the Vaccine Race

BioDelivery Sciences

BioMarin Pharmaceutical

Catalyst Pharmaceuticals

Innoviva

Vertex Pharmaceuticals

Voyager Therapeutics

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Biotech Stocks for Q1 2021

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?

Why Is Novavax (NVAX) Up 52.6% Since Last Earnings Report?

GAITHERSBURG, Md., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Margaret G. McGlynn, R. Ph. to its board as an independent director. Ms. McGlynn brings extensive pharmaceutical industry, vaccine and non-profit experience to her role on the Novavax Board of Directors.

Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors

A rival's setback could translate into a major windfall for this mid-cap biotech company.

Why Novavax Stock Crushed It in November

Are the big gains over? No. But the game is changing.

How to Buy Coronavirus Vaccine Stocks in 2021

It's tricky to pick a winner in the Covid vaccine race, but NVAX stock traders should know that there's room for more than one success story. The post Hold on to Your Novavax Stock and Don't Fear the Competition appeared first on InvestorPlace.

Hold on to Your Novavax Stock and Don't Fear the Competition

The companies with the biggest gains won't necessarily be those with the highest sales of coronavirus vaccines.

$40 Billion COVID Vaccine Market in 2021: These 3 Stocks Are Likely to Be the Biggest Winners

The No. 1 stock of 2020 still has a lot of room to run... and a lot of room to fall.

Is Novavax Still a Buy After Jumping 3,000%?

Costco

International Paper

Olin

Procter & Gamble

Ammo

Vista Outdoor

Wheaton Precious Metals

Under normal circumstances, an outgoing president would congratulate the incoming administration. But we're not living in normal circumstances, which bodes well for these stocks to buy during a rocky transition.

9 Stocks to Buy Despite the Rocky Transition

Combining vaccines for multiple viruses could boost sales.

The Flu Gives This Coronavirus Vaccine Stock A Surprising Edge

GlaxoSmithKline

These three could deliver big for investors once their vaccines are approved for sale.

3 Coronavirus Vaccine Stocks That Still Have Strong Upside

Novavax stock saw some volatility after the company said that it had rescheduled its Phase-3 clinical trial in the US, indicating that it could begin in the coming weeks, instead of starting in November. This marks the second time that the company has delayed its U.S. trials, amid some challenges.

After Facing Delays, Does The Novavax Covid Vaccine Still Matter?

CureVac B.V

If we judge by return on investment, these two mid-cap biotechs may be the ultimate winners of the coronavirus vaccine race.

2 Surprising Coronavirus Vaccine Stocks to Buy Right Now

NVAX stock has already popped on recent vaccine developments, but don't worry. In the months ahead, shares could head even higher.

As Novavax Stock Soars, There's Still Opportunity

North Korean hackers have reportedly coordinated cyberattacks against at least half a dozen drug companies working on coronavirus vaccines and treatments. A notorious hacker group that the US government has called “Kimsuky” targeted the companies in the US, the UK and South Korea in an apparent effort to steal sensitive information that North Korea could.

News for Novavax Stock (NVAX)